Trials / Completed
CompletedNCT02899299
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 605 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | |
| BIOLOGICAL | Ipilimumab | |
| DRUG | Pemetrexed | |
| DRUG | Cisplatin | |
| DRUG | Carboplatin |
Timeline
- Start date
- 2016-11-29
- Primary completion
- 2020-03-25
- Completion
- 2023-04-28
- First posted
- 2016-09-14
- Last updated
- 2024-05-21
- Results posted
- 2021-04-14
Locations
109 sites across 21 countries: United States, Australia, Belgium, Brazil, Chile, China, Colombia, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, South Africa, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02899299. Inclusion in this directory is not an endorsement.